Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | AGER | Q15109 | 1/20 | 0.71 |
| ▸ | SCD | O00767 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290771 | 0.85 | NPC1 (0.79) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL15070451 | 0.85 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL5502572 | 0.84 | AGER (0.76) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4295195 | 0.84 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4287847 | 0.84 | AGER (0.76) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL16378731 | 0.84 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3200814 | 0.84 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2307971 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL28801036 | 0.84 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4293350 | 0.84 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495475-A | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LTD (GB) | 2009-07-29 | — | — | CN | claimed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | claimed |
| EP-1865959-A2 | PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | claimed |
| WO-2006104917-A2 | PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | GLAXO GROUP LIMITED (GB) | 2010-03-18 | — | — | US | disclosed |
| US-20100022542-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2010-01-28 | — | — | US | disclosed |
| US-7582665-B2 | Heterocyclic sulfur compounds and/or prodrugs administered for prophylaxis of thrombocytopenia, anemia or blood disorders | SHIONOGI & CO., LTD. (JP) | 2009-09-01 | — | — | US | disclosed |
| CN-101495475-A | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LTD (GB) | 2009-07-29 | — | — | CN | disclosed |
| US-20090048444-A1 | Process for Preparing Pyrido[2,3-d]pyrimidin-7-one and 3,4-Dihydropyrimido[4,5-d]pyrimidin-2(1H)-one Derivatives | GLAXO GROUP LIMITED | 2009-02-19 | — | — | US | disclosed |
| US-7479558-B2 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2009-01-20 | — | — | US | disclosed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | RAB9A 1737/4885NPC1 4045/4885SMN1; SMN2 2387/4885 |
| US-20090048444-A1 | Process for Preparing Pyrido[2,3-d]pyrimidin-7-one and 3,4-Dihydropyrimido[4,5-d]pyrimidin-2(1H)-one Derivatives | CBR3, CBR1, CYP2S1 | RAB9A 2310/4885NPC1 3983/4885SMN1; SMN2 2341/4885 |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | CYP2S1, CYP2F1, CBR3 | RAB9A 1800/4885NPC1 3552/4885SMN1; SMN2 2198/4885 |
| US-20100022542-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | THPO, MPL, TEK | RAB9A 1898/4885NPC1 3951/4885SMN1; SMN2 1546/4885 |
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | MAPKAPK2, CDC42BPB, MAP4K2 | RAB9A 1298/4885NPC1 2563/4885SMN1; SMN2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.